Introduction

Integrated genome-wide screens of DNA copy number and gene expression in human cancers have accelerated the rate of discovery of amplified and overexpressed genes. However, the biological importance of most of the genes identified in such studies remains unclear. In a recently published paper, we proposed a weight-of-evidence based classification system for identifying individual genes in amplified regions that are probably selected for during tumour development. We have used this approach to comprehensively catalogue genes which are both amplified and overexpressed in cancer. This complements a census of cancer genes for which there is sufficient evidence to support a causal role in sporadic or familial cancer development when mutated. We continue to update this catalogue and release 2 will appear on the 15th November 2010.

We welcome comments, in particular potential papers for inclusion.

Paper: Nature Reviews Cancer 10, 59-64 (January 2010)

Version 2 delayed

Due to unforeseen circumstances version 2 has been delayed for a few days. It was scheduled for release on 15/11/10.

Version 1

Released: 24th December 2009

DOWNLOAD HERE

If you wish to receive notification of subsequent releases please subscribe to the mailing list

Summary Table

For further information on the methodology and definition of Class I, II and III genes please read the Methodology Section.

Cancer type Class III Class II Class I
Acute myeloid leukaemiaTRIB1
BladderYWHAQ, E2F3, YWHAZ, ERBB2, AuroraA/AURKA
BreastSHCA/SHC1, CKS1/CKS1B, RUVBL1, C8orf4, LSM1, FGFR1, BAG4, MTDH, MYC, EMSY/C11orf30, PAK1, CDK4, MDM2, PLA2G10, STARD3, GRB7, RPS6KB1, PPM1D, CCNE1, YWHAB, ZNF217, AuroraA/AURKA, BRK/PTK6CCND1, AIB1/NCOA3ERBB2
ColorectalMYC EGFR
Diffuse large B cell lymphomaREL
EndometrialERBB2
GastricRAB23, MET, MYC, ERBB2, CDC6
GliomaMDM4, AKT3, EGFR, CDK6, MET, CCND2, CDK4, MDM2
Head and neckSCCRO/DCUN1D1
Hepatocellular carcinomaALC1/CHD1L
Hodgkin's lymphomaREL
Laryngeal squamous cell carcinomaFADD
Liver YAP1, cIAP1/BIRC2
LungMYCN, SCCRO/DCUN1D1, EGFR, MET, WHSC1L1, YWHAZ, MYC, CCND1, MDM2, BCL2L2, PAX9, TITF1/NKX2-1, OLC1/KIAA0174, EEF1A2MYCL1, SKP2, NKX2-8
Malignant melanomaMITF, CCND1, CDK4
MedulloblastomaMYC
NeuroblastomaMDM2MYCN
OesophagealPRKCI, ZASC1/ZNF639, SKP2, EGFR, SHH, DYRK2, ERBB2, CCNE1, AuroraA/AURKA
Oral squamous cell carcinomaCCND1, ERBB2
OsteosarcomaCOPS3
OvarianeIF-A2/EIF5A2, MDS/ETV1, EMSY/C11orf30, ERBB2, RPS6KB1, AKT2RAB25, PIK3CA
PancreaticARPC1/ARPC1A, SMURF1, IXL/MED29
PancreatobillaryGATA6
ProstateMYC AR
RetinoblastomaE2F3MDM4
RhabdomyosarcomaMYCN, FGFR1, GPC5
SarcomaJUN, MAP3K5, YEATS4, CDK4, DYRK2MDM2
Soft tissue sarcomaSKP2
Testicular germ cell tumourKIT, KRAS
Wilms' tumourCACNA1E

Contact Us